{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:39:07Z","timestamp":1792618747253,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtho.2026.106129","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:11:39Z","timestamp":1790687499000},"page":"106129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Molly S.C.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Yang","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Yin","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jii-Bum","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorn","family":"Nutzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.106129_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107385","article-title":"Management of HER2 alterations in non-small cell lung cancer - the past, present, and future","volume":"186","author":"N\u00fctzinger","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2026.106129_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.106129_bib3","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, Phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib5","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.106129_bib6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.106129_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa2516969","article-title":"First-line zongertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"394","author":"Heymach","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.106129_bib8","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtho.2026.106129_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jtho.2026.106129_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.jtho.2026.106129_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jtho.2026.106129_bib12","series-title":"Modeling Survival Data: Extending the Cox Model2000","author":"Therneau","year":"2000"},{"key":"10.1016\/j.jtho.2026.106129_bib13","author":"Kassambara"},{"key":"10.1016\/j.jtho.2026.106129_bib14","series-title":"Chapter 7. Systematic Reviews of Etiology and Risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.jtho.2026.106129_bib15","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib16","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.jtho.2025.09.706","article-title":"P2.10.12 trastuzumab deruxtecan in patients from China with pretreated HER2-mutant NSCLC: final results from the DESTINY-Lung05 study","volume":"20","author":"Cheng","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2026.106129_bib18","doi-asserted-by":"crossref","first-page":"S613","DOI":"10.1016\/j.jtho.2025.09.1159","article-title":"PT2.12.03 zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1","volume":"20","author":"Ruiter","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2026.106129_bib20","article-title":"Acquired ERBB2 amplification and overexpression as on-target resistance mechanisms to zongertinib with subsequent response to trastuzumab-deruxtecan: a case report","volume":"7","author":"McMahon","year":"2026","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2026.106129_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.106129_bib22","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1158\/1538-7445.AM2026-7025","article-title":"Abstract 7025: Mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance","volume":"86","author":"Shibata","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2026.106129_bib23","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou","year":"2024","journal-title":"MedComm 2020"},{"key":"10.1016\/j.jtho.2026.106129_bib24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.106129_bib25","article-title":"Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs","volume":"21","author":"Nilsson","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103708","article-title":"ERBB2-activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer","volume":"21","author":"Stockhammer","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.106129_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/2159-8290.CD-25-0605","article-title":"Sevabertinib, a reversible HER2 inhibitor with activity in lung cancer","volume":"16","author":"Siegel","year":"2026","journal-title":"Cancer Discov"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426025827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426025827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:00:53Z","timestamp":1792616453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426025827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S1556086426025827"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.106129","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of HER2-Directed Therapies for Advanced HER2-Mutant NSCLC: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.106129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106129"}}